series c news from FierceBiotech
NewsKythera garners $40M in third venture round
LA-based Kythera Biopharmaceuticals is looking for a key assist in Japan from a new investor. JAFCO has led a $40 million Series C for the biotech developer of "aesthetic" therapies. BBT Capital Read more...
ALSO NOTED: Lilly completes massive expansion project; Revance garners new venture funds; Gamers target protein chemistry; and
> After laboring for 10 long years, Eli Lilly says it's wrapped a massive, $1 billion expansion program for its new research hub. Read more...
BioVascular raises $10.87M
With the help of lead investor BB Biotech Ventures, BioVascular rounded up $10.87 million in series C financing. The San Diego, CA-based company plans on using the money to complete clinical trials Read more...
Acceleron garners $31M Series C
Just months after raising its second venture round, Acceleron Pharma has announced a $31 million Series C. Much of that money Read more...
ALSO NOTED: Genmab gets milestone payment from Roche; Mylan appoints CEO; and much more...
> Roche has filed a Clinical Trial Application for a Genmab antibody developed under the companies' collaboration. The CTA triggers a milestone payment for Genmab, the amount of which is Read more...
AdvanDX finds $15M in third VC round
France's BioMerieux has signed on as an investor for AdvanDX, a diagnostics company based in Woburn, MA, contributing to a $15 million Series C round for the company. The money is earmarked for Read more...
Aldagen adds $9M in new venture funds
Durham, NC-based Aldagen has added $9 million in new money for its third round, bringing total investment in the Series C to $23 million. That money will be put to use developing new stem cell Read more...
Topigen adds $25M in new venture funds
Canada's Topigen Pharmaceuticals has gained $25 million in venture support for its clinical programs in respiratory disorders. The round brings the biotech's total financing to $71 million to date. Read more...
ALSO NOTED: BioProcessors gets $10M round; Regeneron therapy gains priority review status; FermaVir reveals positive preclinica
> LSP BioVentues has led a $10 million Series C equity investment round in Woburn, MA-based BioProcessors Corporation. The company provides micro-engineered solutions for biopharmaceutical process Read more...
Press Release: Ception Therapeutics Raises $63M in Series C FinancingPress Release: Ception Therapeutics Raises $63M in Series C Financing Read more... | Press ReleasesPRESS RELEASE: LSP Participates in $10 million Series C investment in BioProcessorsLSP Participates in $10 million Series C investment in BioProcessors LSP BioVentues announces today that it has lead the closing of a $10 million Series C equity investment round in BioProcessors Read more... |
Paid Research Reports
- Leading Drug Delivery Companies and Technologies: Competitive landscape, company profiles and technological developments
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets